Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group.

ABSTRACT: Approximately 50% of tubo-ovarian high-grade serous carcinomas (HGSCs) have functional homologous recombination-mediated (HR) DNA repair, so-called HR-proficient tumors, which are often associated with primary platinum resistance (relapse within six months after completion of first-line therapy), minimal benefit from poly(ADP-ribose) polymerase (PARP) inhibitors, and shorter survival. HR-proficient tumors comprise multiple molecular subtypes including cases with CCNE1 amplification, AKT2 amplification or CDK12 alteration, and are often characterized as "cold" tumors with fewer infiltrating lymphocytes and decreased expression of PD-1/PD-L1. Several new treatment approaches aim to manipulate these negative prognostic features and render HR-proficient tumors more suscept

SUBMITTER: Stiegeler N 

PROVIDER: S-EPMC11183307 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature